Epizyme, Inc. (EPZM): Price and Financial Metrics


Epizyme, Inc. (EPZM): $1.47

-0.02 (-1.34%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add EPZM to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

EPZM Stock Price Chart Interactive Chart >

Price chart for EPZM

EPZM Price/Volume Stats

Current price $1.47 52-week high $5.80
Prev. close $1.49 52-week low $0.41
Day low $1.47 Volume 22,276,000
Day high $1.50 Avg. volume 3,225,203
50-day MA $1.21 Dividend yield N/A
200-day MA $1.80 Market Cap 247.44M

Epizyme, Inc. (EPZM) Company Bio


Epizyme, Inc. discovers and develops epigenetic therapies for cancer patients. The company was founded in 2007 and is based in Cambridge, Massachusetts.


EPZM Latest News Stream


Event/Time News Detail
Loading, please wait...

EPZM Latest Social Stream


Loading social stream, please wait...

View Full EPZM Social Stream

Latest EPZM News From Around the Web

Below are the latest news stories about EPIZYME INC that investors may wish to consider to help them evaluate EPZM as an investment opportunity.

Aptinyx's (APTX) Mid-Stage Fibromyalgia Study Fails to Meet Goal

Aptinyx (APTX) reports disappointing data from a mid-stage study assessing NYX-2925 for the treatment of fibromyalgia. Stocks decline

Yahoo | August 12, 2022

Epizyme (EPZM) Q2 Earnings Beat Estimates, Revenues Up Y/Y

Epizyme (EPZM) posts a narrower-than-expected loss in the second quarter. Revenues beat estimates.

Yahoo | August 10, 2022

The past five years for Epizyme (NASDAQ:EPZM) investors has not been profitable

Epizyme, Inc. ( NASDAQ:EPZM ) shareholders will doubtless be very grateful to see the share price up 219% in the last...

Yahoo | August 10, 2022

Epizyme (EPZM) Reports Q2 Loss, Tops Revenue Estimates

Epizyme (EPZM) delivered earnings and revenue surprises of 41.67% and 172.20%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | August 9, 2022

Epizyme Reports Second Quarter 2022 Financial Results and Provides Business Update

CAMBRIDGE, Mass., August 09, 2022--Epizyme (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering transformative therapies for cancer patients against novel epigenetic targets, today reported second quarter 2022 financial results and provided a business update.

Yahoo | August 9, 2022

Read More 'EPZM' Stories Here

EPZM Price Returns

1-mo N/A
3-mo N/A
6-mo -1.34%
1-year -1.34%
3-year -93.25%
5-year -91.09%
YTD N/A
2022 0.00%
2021 -76.98%
2020 -55.85%
2019 299.35%
2018 -50.92%

Continue Researching EPZM

Want to see what other sources are saying about Epizyme Inc's financials and stock price? Try the links below:

Epizyme Inc (EPZM) Stock Price | Nasdaq
Epizyme Inc (EPZM) Stock Quote, History and News - Yahoo Finance
Epizyme Inc (EPZM) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6629 seconds.